RxDoctor Payments Data

John Floyd, MD

Internal Medicine · Spokane, WANPI 1114913621

Payments from drug & device makers

$515in general payments, 2019–2025

Across 26 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$174
  • Johnson & Johnson$107
  • AstraZeneca$45
  • Sanofi Pasteur Inc.$26
  • Otsuka America Pharmaceutical, Inc.$24
  • Sumitomo Pharma America, Inc.$23
  • plus $117 from 7 others

What the payments were for

  • Food & beverage$515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$515 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$254,253
Medicare patients
559
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$146,281
OzempicSemaglutide93$136,541
XareltoRivaroxaban73$93,266
JardianceEmpagliflozin73$74,764
JanuviaSitagliptin Phosphate23$26,801
TrulicityDulaglutide21$23,296
MyrbetriqMirabegron33$22,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog97$18,143
MounjaroTirzepatide16$17,993
Potassium Chloride378$9,293
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen340$7,717
OxycontinOxycodone Hcl13$7,285
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$7,022
Losartan Potassium612$6,812
Omeprazole414$6,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$146,281159 claims
Novo NordiskOzempic$174$136,54193 claims
Johnson & JohnsonXarelto$107$93,26673 claims
Boehringer IngelheimJardiance$22$74,76473 claims
MerckJanuvia, Dulera$12$31,66737 claims
GSKTrelegy Ellipta$16$5,56911 claims
AstraZenecaSymbicort$45$3,60617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →